Skip to main content
. Author manuscript; available in PMC: 2022 Sep 10.
Published in final edited form as: J Control Release. 2021 Jul 16;337:168–178. doi: 10.1016/j.jconrel.2021.07.026

Figure 6. sHDL nanodiscs for vaccination against mutated tumor-specific neoantigen.

Figure 6.

A) C57BL/6 mice were inoculated subcutaneously with 1x106 MC-38 tumor cells and immunized with various vaccine formulations (15.5 nmol Ag peptide, 2.3 nmol CpG, or 60 μg polyICLC) on days 10 and 17. In addition, 100 μg α-PD-1 IgG was administered on days 1 and 4 after each vaccination. B) IFN-γ ELISPOT assay was performed on day 35 after ex vivo restimulation of splenocytes with 10 μg/mL Adpgk peptide, and C) representative ELISPOT wells are shown. D-F) Vaccinated mice were monitored for D,E) the tumor growth and F) survival. Data represent mean ± SEM, n = 7. Statistical significance was calculated by B) one-way ANOVA or E) two-away ANOVA, followed by the Tukey’s multiple comparisons post-test, or F) by Kaplan-Meier survival analysis with Log-rank Mantel-Cox. *P < 0.05, **P< 0.01, ***P < 0.001, and ****P < 0.0001.